[Near fatal intoxication with the novel psychoactive substance 25C-NBOMe].
BACKGROUND
Effects of overdosing 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) have not been previously described. Currently the drug is legal in most parts of the world.


METHODS
The case of a 19-year-old man who had nasally administered 2 mg of 25C-NBOMe, a novel psychoactive drug, within 1 h is described. Two hours later, he experienced a generalized seizure. Due to loss of consciousness and low oxygen saturation, he required mechanical ventilation. On day 2, he could be extubated without need for supplemental oxygen and appeared to recover quickly. On day 3, he developed acute kidney failure requiring hemofiltration. His condition continued to deteriorate with development of acute lung failure on day 4. He again required non-invasive and subsequently invasive ventilation with high demands for oxygen and high supporting pressure. On days 7 and 8 his condition became life threatening due to difficulties to achieve sufficient oxygenation even with a FIO2 of 80 %. After 13 days in the intensive care unit, he finally recovered without sequelae.


CONCLUSIONS
In summary, 2 mg of 25C-NBOMe placed a young healthy man in a critical situation both acutely a few hours after ingestion due to a generalized seizure and during the subsequent days due to multiple organ failure.
Abteilung für Kardiologie und konservative Intensivmedizin, Klinikum Herford, Schwarzenmoorstr. 70, 32049, Herford, Deutschland, steffen.grautoff@klinikum-herford.de.
S
S
Grautoff
J
J
Kähler
D000281:Administration, Intranasal; D001596:Benzylamines / Q000506:poisoning*; D003422:Critical Care / Q000379:methods*; D062787:Drug Overdose / Q000209:etiology / Q000628:therapy*; D006213:Hallucinogens / Q000506:poisoning*; D006801:Humans; D008297:Male; D009102:Multiple Organ Failure / Q000139:chemically induced* / Q000628:therapy; D010627:Phenethylamines / Q000506:poisoning*; D011619:Psychotropic Drugs / Q000506:poisoning*; D055815:Young Adult
D001596:Benzylamines; D006213:Hallucinogens; D010627:Phenethylamines; D011619:Psychotropic Drugs; C000601106:2-(4-chloro-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine